Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309266 | 0.90 | MEN1 (0.40) | LMNAMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4309278 | 0.90 | LMNA (0.39) | LMNAMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4314165 | 0.88 | PTGDR2 (0.41) | LMNAMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4312359 | 0.79 | SMN1; SMN2 (0.38) | LMNAMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4311630 | 0.78 | PTGDR2 (0.39) | LMNAMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4309050 | 0.75 | PTGDR2 (0.43) | LMNAMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4311723 | 0.75 | ALDH1A1 (0.37) | LMNAMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4309081 | 0.74 | AURKA (0.37) | LMNAMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL4309569 | 0.74 | PTGDR2 (0.43) | LMNAMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL14160561 | 0.73 | ALDH1A1 (0.40) | ALDH1A1PTGS2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962830-B1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7605266-B2 | Azaindole inhibitors of Aurora kinases | SMITHKLINE BEECHAM (US) | 2009-10-20 | — | — | US | disclosed |
| US-7495102-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | GLAXOSMITHKLINE LLC | 2008-12-11 | — | — | US | disclosed |
| US-7419988-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORP (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | LMNA 3007/4885MEN1 946/4885KMT2A 105/4885 |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | LMNA 3007/4885MEN1 946/4885KMT2A 105/4885 |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | LMNA 3007/4885MEN1 946/4885KMT2A 105/4885 |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | AURKA, AURKC, AURKB | LMNA 3144/4885MEN1 400/4885KMT2A 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.